Jeffrey Ravetch
Overview
Explore the profile of Jeffrey Ravetch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wohner M, Brechtelsbauer S, Friedrich N, Vorsatz C, Bulang J, Liang C, et al.
Cell Rep
. 2024 Feb;
43(2):113757.
PMID: 38354088
Understanding the mechanisms underlying cytotoxic immunoglobulin G (IgG) activity is critical for improving therapeutic antibody activity and inhibiting autoantibody-mediated tissue pathology. While prior research highlights the important role of the...
2.
Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, et al.
Nat Cancer
. 2023 Oct;
4(12):1675-1692.
PMID: 37872381
Despite recent advances in the treatment of acute myeloid leukemia (AML), there has been limited success in targeting surface antigens in AML, in part due to shared expression across malignant...
3.
Knorr D, Leidner R, Jensen S, Meng R, Jones A, Ballesteros-Merino C, et al.
bioRxiv
. 2023 Jan;
PMID: 36711504
Despite pre-clinical murine data supporting T regulatory (Treg) cell depletion as a major mechanism by which anti-CTLA-4 antibodies function in vivo, the two main antibodies tested in patients (ipilimumab and...
4.
Pradier L, Blanchard-Bregeon V, Bohme A, Debeir T, Menager J, Benoit P, et al.
Alzheimers Res Ther
. 2018 Nov;
10(1):117.
PMID: 30486882
Background: Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer's disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted...
5.
Wagh K, Seaman M, Zingg M, Fitzsimons T, Barouch D, Burton D, et al.
PLoS Pathog
. 2018 Mar;
14(3):e1006860.
PMID: 29505593
There is great interest in passive transfer of broadly neutralizing antibodies (bnAbs) and engineered bispecific antibodies (Abs) for prevention of HIV-1 infections due to their in vitro neutralization breadth and...
6.
Ravetch J
Nat Immunol
. 2010 Feb;
11(3):183-5.
PMID: 20157296
Jeffrey Ravetch describes how he came to identify the in vivo function of the once mysterious Fc receptors.
7.
Ravetch J
Proc Natl Acad Sci U S A
. 2009 May;
106(19):7689-91.
PMID: 19416845
No abstract available.
8.
Delgado M, Coviello S, Monsalvo A, Melendi G, Hernandez J, Batalle J, et al.
Nat Med
. 2008 Dec;
15(1):34-41.
PMID: 19079256
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. A formalin-inactivated RSV vaccine was used to immunize children and elicited nonprotective, pathogenic antibody. Immunized infants experienced increased...
9.
10.
Steinman R, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, et al.
Ann N Y Acad Sci
. 2003 May;
987:15-25.
PMID: 12727620
The avoidance of autoimmunity requires mechanisms to actively silence or tolerize self reactive T cells in the periphery. During infection, dendritic cells are not only capturing microbial antigens, but also...